Search Result

Results for "

DNA-encoded libraries

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Biochemical Assay Reagents (1) Drug Derivative (1) Drug Intermediate (1) Histone Acetyltransferase (1) Interleukin Related (1) JAK (2) PARP (2) Phosphoglycerate Dehydrogenase (PHGDH) (1)
By Research Areas:	Cancer (4) Inflammation/Immunology (3)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W002805

2-Bromoisonicotinic acid 1 Publications Verification	Drug Intermediate	Others
2-Bromoisonicotinic acid is a (hetero)aryl bromide building block and DNA-conjugated headpiece for photochemical C-H heteroarylation in DNA-encoded library synthesis. 2-Bromoisonicotinic acid generates a nucleophilic pyridyl radical intermediate. 2-Bromoisonicotinic acid, when conjugated to DNA, leaves electrophilic handles intact for subsequent library diversification .

HY-42045

Pyrimidine-5-boronic acid pinacol ester	Drug Derivative	Others
Pyrimidine-5-boronic acid pinacol ester is a derivative of Boronic acid. Boronic acid is an intermediate commonly used in organic synthesis reactions and can be used as a key reagent in the Suzuki-Miyaura reaction. It generates organic free radicals through oxygen-mediated oxidation and exhibits potential mutagenic activity. Boronic acid is mainly used in research in the fields of drug synthesis and catalytic reactions. Pyrimidine-5-boronic acid pinacol ester serves as a building block in DNA-compatible one-pot click chemistry for synthesis of DNA-encoded libraries .

HY-152197

Tankyrase-IN-3	PARP	Cancer
Tankyrase-IN-3 is a tankyrase 1 (TNKS1) inhibitor with an IC₅₀ value of 22 nM. Tankyrase-IN-3 can be used for the research of cancer .

HY-178763

DEL1187-126-28-16	JAK	Inflammation/Immunology
DEL1187-126-28-16 is a JAK3 inhibitor with IC₅₀s of 10 and 0.97 nM against JAK3 WT in 0 and 60 min. DEL1187-126-28-16 has no activity at all towards the C909S mutant, JAK1, JAK2, and TYK2. DEL1187-126-28-16 can be used for the study of immune-mediated diseases .

HY-178755

DEL1187-126-5-80	JAK	Inflammation/Immunology
DEL1187-126-5-80 is a JAK3 inhibitor with IC₅₀s of 52 and 7.9 nM against JAK3 WT in 0 and 60 min. DEL1187-126-5-80 has no activity at all towards the C909S mutant, JAK1, JAK2, and TYK2. DEL1187-126-5-80 can be used for the study of immune-mediated diseases .

HY-178714

JNJ627	Interleukin Related	Inflammation/Immunology
JNJ627 is a small molecule allosteric inhibitor of IL-17A with a K_D of 92 nM. JNJ627 effectively inhibits the binding of IL-17A and IL-17RA, with an IC₅₀ value of 16 nM. JNJ627 is capable of inhibiting the secretion of G-CSF (granulocyte colony-stimulating factor) caused by IL-17A stimulation. JNJ627 can be used for the study of autoimmune diseases (such as psoriasis) .

HY-159587

P300-IN-4	Histone Acetyltransferase	Cancer
P300-IN-4 (compound 6) is a (p300) inhibitor with the IC₅₀ of 12.2 μM.

HY-152198

Tankyrase-IN-4	PARP	Cancer
Tankyrase-IN-4 is a tankyrase 1 (TNKS1) inhibitor with an IC₅₀ value of 0.8 nM. Tankyrase-IN-4 can be used for the research of cancer .

HY-185129

Headpiece	Biochemical Assay Reagents	Others
Headpiece is a short, covalently linked double-stranded DNA (dsDNA). It is designed as the starting point of DNA-Encoded Libraries (DELs) synthesis. In each chemical synthesis step, the compounds are encoded by enzymatically ligating the respective DNA tags to the Headpiece. Finally, a closing primer containing the distal primer-binding site for PCR amplification is added to complete the library synthesis/encoding.

HY-179652

PHGDH-IN-6	Phosphoglycerate Dehydrogenase (PHGDH)	Cancer
PHGDH-IN-6 (Compound L5) is a PHGDH allosteric inhibitor with an IC₅₀ of 2.5 μM. PHGDH-IN-6 can be used for studying diseases related to serine synthesis .

Cat. No.	Product Name

HY-LD004

DEL Covalent Library	14 million compounds
DEL technology enables the simultaneous screening of millions or billions of compounds in a single tube by covalently linking each small molecule with a unique DNA sequence. Traditional DEL screening primarily focuses on identifying non-covalent binding molecules, where interactions with the target are reversible. In contrast, DNA‑encoded covalent library is an ultra‑high‑throughput screening library developed on the basis of conventional DNA‑encoded library technology. It incorporates controllable electrophilic covalent warheads capable of forming irreversible covalent bonds with amino acid residues at the active sites of target proteins, including Cys, Lys, Ser, Tyr, and others. This covalent binding enhances binding affinity, prolongs residence time at the target site, and has the potential to overcome challenges associated with traditional non-covalent inhibitors, such as drug resistance or off-target effects. Each compound in the library contains both a binding domain and an electrophilic warhead. It first recognizes and binds to the target through non covalent interactions, and then forms a stable covalent bond with key amino acid residues to achieve irreversible inhibition. This library is specifically designed for the discovery of potent, long lasting, and highly selective covalent inhibitors, particularly for undruggable targets such as kinases, GPCRs, proteases, and mutant oncoproteins. Each molecule is uniquely labeled with a DNA barcode for molecular identification and sequencing decoding. This library is an advanced and highly diverse collection, consists of 35 independent sub-libraries with a total scaleof 14 million compounds, It incorporates over 14 experimentally validated covalent warheads capable of targeting cysteine, lysine, arginine, aspartic acid and glutamic acid. This library is constructed with diverse drug like core scaffolds and integrated controllable covalent warheads, it features structural diversity, reaction spec

DEL Covalent Library

14 million compounds

DEL technology enables the simultaneous screening of millions or billions of compounds in a single tube by covalently linking each small molecule with a unique DNA sequence. Traditional DEL screening primarily focuses on identifying non-covalent binding molecules, where interactions with the target are reversible. In contrast, DNA‑encoded covalent library is an ultra‑high‑throughput screening library developed on the basis of conventional DNA‑encoded library technology. It incorporates controllable electrophilic covalent warheads capable of forming irreversible covalent bonds with amino acid residues at the active sites of target proteins, including Cys, Lys, Ser, Tyr, and others. This covalent binding enhances binding affinity, prolongs residence time at the target site, and has the potential to overcome challenges associated with traditional non-covalent inhibitors, such as drug resistance or off-target effects.

Each compound in the library contains both a binding domain and an electrophilic warhead. It first recognizes and binds to the target through non covalent interactions, and then forms a stable covalent bond with key amino acid residues to achieve irreversible inhibition. This library is specifically designed for the discovery of potent, long lasting, and highly selective covalent inhibitors, particularly for undruggable targets such as kinases, GPCRs, proteases, and mutant oncoproteins. Each molecule is uniquely labeled with a DNA barcode for molecular identification and sequencing decoding.

This library is an advanced and highly diverse collection, consists of 35 independent sub-libraries with a total scaleof 14 million compounds, It incorporates over 14 experimentally validated covalent warheads capable of targeting cysteine, lysine, arginine, aspartic acid and glutamic acid. This library is constructed with diverse drug like core scaffolds and integrated controllable covalent warheads, it features structural diversity, reaction spec

HY-LD002

DEL B Kit Regular Library	100 billion compounds
The discovery of hit molecule is a cornerstone of drug development. Among the diverse tools available, DNA-encoded libraries have emerged a revolutionary platform for high-throughput screening. Compared with traditional HTS, DEL features shorter screening processes, lower costs, simpler assays, and larger library capacities. DEL Construction utilizes split-and-pool synthesis, a combinatorial chemistry approach that involves iterative splitting, reaction, and pooling. This strategy enables rapid, exponential assembly of fragments in minimal steps without the need for individual compound synthesis andassoicicated isolation or purification steps, thus greatly reducing overall costs. The technology enables simultaneous affinity screeningof massive compound collections to target proteins in a single step. By coupling chemical structures with unique DNA barcodes, each compound is tagged with a distinct DNA sequence for convenient tracking and decoding.DELs readily enable the construction and efficient screening of libraries containing millions to billions of compounds. As a result, DEL screening combines the dual advantages of high efficiency and low cost, making DEL a transformative technology in modern drug discovery. The DEL kit consists of 50 independent libraries with a total scale of 100 billion compounds. It is constructed through stepwise combinatorial chemistry strategies involving 2-, 3-, and 4-round synthesis. By employing diverse scaffolds and flexible linking strategies, it encompasses various ring systems, linear frameworks, and heterocyclic structures. Screening can be achieved solely through affinity, independent of target-specific activity detection methods. This library is suitable for DEL screening against a wide range of targets.

DEL B Kit Regular Library

100 billion compounds

The discovery of hit molecule is a cornerstone of drug development. Among the diverse tools available, DNA-encoded libraries have emerged a revolutionary platform for high-throughput screening. Compared with traditional HTS, DEL features shorter screening processes, lower costs, simpler assays, and larger library capacities.

DEL Construction utilizes split-and-pool synthesis, a combinatorial chemistry approach that involves iterative splitting, reaction, and pooling. This strategy enables rapid, exponential assembly of fragments in minimal steps without the need for individual compound synthesis andassoicicated isolation or purification steps, thus greatly reducing overall costs. The technology enables simultaneous affinity screeningof massive compound collections to target proteins in a single step. By coupling chemical structures with unique DNA barcodes, each compound is tagged with a distinct DNA sequence for convenient tracking and decoding.DELs readily enable the construction and efficient screening of libraries containing millions to billions of compounds. As a result, DEL screening combines the dual advantages of high efficiency and low cost, making DEL a transformative technology in modern drug discovery.

The DEL kit consists of 50 independent libraries with a total scale of 100 billion compounds. It is constructed through stepwise combinatorial chemistry strategies involving 2-, 3-, and 4-round synthesis. By employing diverse scaffolds and flexible linking strategies, it encompasses various ring systems, linear frameworks, and heterocyclic structures. Screening can be achieved solely through affinity, independent of target-specific activity detection methods. This library is suitable for DEL screening against a wide range of targets.

Cat. No.	Product Name	Type

HY-W002805

2-Bromoisonicotinic acid 1 Publications Verification	Biochemical Assay Reagents
2-Bromoisonicotinic acid is a (hetero)aryl bromide building block and DNA-conjugated headpiece for photochemical C-H heteroarylation in DNA-encoded library synthesis. 2-Bromoisonicotinic acid generates a nucleophilic pyridyl radical intermediate. 2-Bromoisonicotinic acid, when conjugated to DNA, leaves electrophilic handles intact for subsequent library diversification .

HY-42045

Pyrimidine-5-boronic acid pinacol ester	Biochemical Assay Reagents
Pyrimidine-5-boronic acid pinacol ester is a derivative of Boronic acid. Boronic acid is an intermediate commonly used in organic synthesis reactions and can be used as a key reagent in the Suzuki-Miyaura reaction. It generates organic free radicals through oxygen-mediated oxidation and exhibits potential mutagenic activity. Boronic acid is mainly used in research in the fields of drug synthesis and catalytic reactions. Pyrimidine-5-boronic acid pinacol ester serves as a building block in DNA-compatible one-pot click chemistry for synthesis of DNA-encoded libraries .

Pyrimidine-5-boronic acid pinacol ester

Biochemical Assay Reagents

Pyrimidine-5-boronic acid pinacol ester is a derivative of Boronic acid. Boronic acid is an intermediate commonly used in organic synthesis reactions and can be used as a key reagent in the Suzuki-Miyaura reaction. It generates organic free radicals through oxygen-mediated oxidation and exhibits potential mutagenic activity. Boronic acid is mainly used in research in the fields of drug synthesis and catalytic reactions. Pyrimidine-5-boronic acid pinacol ester serves as a building block in DNA-compatible one-pot click chemistry for synthesis of DNA-encoded libraries .

Cat. No.	Product Name		Classification

HY-178755

DEL1187-126-5-80		Alkynes
DEL1187-126-5-80 is a JAK3 inhibitor with IC₅₀s of 52 and 7.9 nM against JAK3 WT in 0 and 60 min. DEL1187-126-5-80 has no activity at all towards the C909S mutant, JAK1, JAK2, and TYK2. DEL1187-126-5-80 can be used for the study of immune-mediated diseases .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.